JP2021522348A5 - - Google Patents
Info
- Publication number
- JP2021522348A5 JP2021522348A5 JP2021510509A JP2021510509A JP2021522348A5 JP 2021522348 A5 JP2021522348 A5 JP 2021522348A5 JP 2021510509 A JP2021510509 A JP 2021510509A JP 2021510509 A JP2021510509 A JP 2021510509A JP 2021522348 A5 JP2021522348 A5 JP 2021522348A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methylsulfonyl
- methoxyphenyl
- ethoxy
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810407741 | 2018-05-02 | ||
| CN201810407741.X | 2018-05-02 | ||
| PCT/CN2019/085327 WO2019210864A1 (zh) | 2018-05-02 | 2019-04-30 | 噻吩衍生物的晶型 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522348A JP2021522348A (ja) | 2021-08-30 |
| JP2021522348A5 true JP2021522348A5 (enExample) | 2022-05-09 |
| JP7542523B2 JP7542523B2 (ja) | 2024-08-30 |
Family
ID=68386284
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561687A Active JP7481263B2 (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の結晶形 |
| JP2021510510A Pending JP2021523935A (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の固体形態 |
| JP2021510509A Active JP7542523B2 (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の結晶形 |
| JP2020561683A Active JP7477459B2 (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の結晶形 |
| JP2023204100A Withdrawn JP2024026251A (ja) | 2018-05-02 | 2023-12-01 | チオフェン誘導体の結晶形 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561687A Active JP7481263B2 (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の結晶形 |
| JP2021510510A Pending JP2021523935A (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の固体形態 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561683A Active JP7477459B2 (ja) | 2018-05-02 | 2019-04-30 | チオフェン誘導体の結晶形 |
| JP2023204100A Withdrawn JP2024026251A (ja) | 2018-05-02 | 2023-12-01 | チオフェン誘導体の結晶形 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11396518B2 (enExample) |
| EP (5) | EP3800190A4 (enExample) |
| JP (5) | JP7481263B2 (enExample) |
| KR (4) | KR102686835B1 (enExample) |
| CN (7) | CN116947878B (enExample) |
| AU (4) | AU2019262282B2 (enExample) |
| BR (4) | BR112020021976A2 (enExample) |
| CA (4) | CA3213055A1 (enExample) |
| DK (1) | DK3789389T3 (enExample) |
| ES (1) | ES3047059T3 (enExample) |
| FI (1) | FI3789389T3 (enExample) |
| PL (1) | PL3789389T3 (enExample) |
| PT (1) | PT3789389T (enExample) |
| WO (4) | WO2019210869A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3789389T3 (pl) * | 2018-05-02 | 2026-03-16 | Tianjin Hemay Pharmaceutical Co., Ltd. | Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu |
| WO2025103428A1 (zh) * | 2023-11-14 | 2025-05-22 | 赣州和美药业股份有限公司 | 中重度斑块型银屑病的治疗 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| AU2003243153A1 (en) * | 2002-04-23 | 2003-11-10 | Dr. Reddy's Laboratories Limited | Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof |
| CN101186612B (zh) | 2006-11-15 | 2012-10-03 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用 |
| KR101514866B1 (ko) | 2009-05-14 | 2015-04-24 | 티안진 헤메이 바이오-텍 컴퍼니 리미티드 | 티오펜 유도체 |
| US8946474B2 (en) * | 2010-06-30 | 2015-02-03 | Leo Pharma A/S | Polymorphic form of a calcimimetic compound |
| CN105793251B (zh) * | 2013-12-05 | 2018-10-12 | 豪夫迈·罗氏有限公司 | 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物 |
| WO2016010178A1 (ko) * | 2014-07-18 | 2016-01-21 | 주식회사 녹십자 | 5-클로로-ｎ-({(5ｓ)-2-옥소-3-[4-(5,6-디하이드로-4h-[1,2,4]트리아진-1-일)페닐]-1,3-옥사졸리딘-5-일}메틸)티오펜-2-카르복사미드 메탄설폰산염의 신규 결정형 및 이를 포함하는 약학 조성물 |
| EP3144393A1 (en) * | 2015-09-18 | 2017-03-22 | LEK Pharmaceuticals d.d. | A synthetic pathway towards apremilast |
| CN107417626B (zh) * | 2016-05-23 | 2020-01-24 | 江苏奥赛康药业有限公司 | 一种2-氨基嘧啶类化合物的多晶型形式 |
| CN107474057B (zh) * | 2016-06-07 | 2021-03-12 | 天津药物研究院有限公司 | (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途 |
| US10570147B2 (en) * | 2017-06-13 | 2020-02-25 | Biotheryx, Inc. | Bicyclic compounds and methods of use |
| EP3644860B1 (en) * | 2017-06-30 | 2024-05-08 | Trophy | An extra oral dental imaging apparatus with patient positioning accessory detection |
| PL3789389T3 (pl) | 2018-05-02 | 2026-03-16 | Tianjin Hemay Pharmaceutical Co., Ltd. | Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu |
-
2019
- 2019-04-30 PL PL19797143.5T patent/PL3789389T3/pl unknown
- 2019-04-30 CN CN202310657955.3A patent/CN116947878B/zh active Active
- 2019-04-30 BR BR112020021976-2A patent/BR112020021976A2/pt unknown
- 2019-04-30 WO PCT/CN2019/085360 patent/WO2019210869A1/zh not_active Ceased
- 2019-04-30 JP JP2020561687A patent/JP7481263B2/ja active Active
- 2019-04-30 CN CN201910364512.9A patent/CN110437250B/zh active Active
- 2019-04-30 KR KR1020207033658A patent/KR102686835B1/ko active Active
- 2019-04-30 JP JP2021510510A patent/JP2021523935A/ja active Pending
- 2019-04-30 EP EP19796979.3A patent/EP3800190A4/en not_active Withdrawn
- 2019-04-30 EP EP19795994.3A patent/EP3789387B1/en active Active
- 2019-04-30 CN CN202310699133.1A patent/CN116854705B/zh active Active
- 2019-04-30 EP EP19797143.5A patent/EP3789389B1/en active Active
- 2019-04-30 JP JP2021510509A patent/JP7542523B2/ja active Active
- 2019-04-30 CN CN202310701814.7A patent/CN116836178A/zh active Pending
- 2019-04-30 KR KR1020207033791A patent/KR102701245B1/ko active Active
- 2019-04-30 KR KR1020207034757A patent/KR102839924B1/ko active Active
- 2019-04-30 US US17/052,077 patent/US11396518B2/en active Active
- 2019-04-30 EP EP19796726.8A patent/EP3789388B1/en active Active
- 2019-04-30 PT PT197971435T patent/PT3789389T/pt unknown
- 2019-04-30 AU AU2019262282A patent/AU2019262282B2/en active Active
- 2019-04-30 CA CA3213055A patent/CA3213055A1/en active Pending
- 2019-04-30 WO PCT/CN2019/085352 patent/WO2019210867A1/zh not_active Ceased
- 2019-04-30 WO PCT/CN2019/085342 patent/WO2019210865A1/zh not_active Ceased
- 2019-04-30 CN CN201910365332.2A patent/CN110437251B/zh active Active
- 2019-04-30 CN CN201910364369.3A patent/CN110437249B/zh active Active
- 2019-04-30 JP JP2020561683A patent/JP7477459B2/ja active Active
- 2019-04-30 DK DK19797143.5T patent/DK3789389T3/da active
- 2019-04-30 EP EP24152184.8A patent/EP4335515A3/en not_active Withdrawn
- 2019-04-30 US US17/052,131 patent/US12180222B2/en active Active
- 2019-04-30 CA CA3098927A patent/CA3098927C/en active Active
- 2019-04-30 CA CA3098931A patent/CA3098931C/en active Active
- 2019-04-30 CN CN202310651520.8A patent/CN116813637A/zh not_active Withdrawn
- 2019-04-30 US US17/052,025 patent/US11274104B2/en active Active
- 2019-04-30 AU AU2019263865A patent/AU2019263865B2/en active Active
- 2019-04-30 AU AU2019262284A patent/AU2019262284A1/en not_active Abandoned
- 2019-04-30 BR BR112020022190-2A patent/BR112020022190A2/pt active Search and Examination
- 2019-04-30 CA CA3099072A patent/CA3099072A1/en not_active Abandoned
- 2019-04-30 WO PCT/CN2019/085327 patent/WO2019210864A1/zh not_active Ceased
- 2019-04-30 KR KR1020207034790A patent/KR20210022557A/ko not_active Ceased
- 2019-04-30 FI FIEP19797143.5T patent/FI3789389T3/fi active
- 2019-04-30 ES ES19797143T patent/ES3047059T3/es active Active
- 2019-04-30 BR BR112020021945-2A patent/BR112020021945A2/pt active Search and Examination
- 2019-04-30 US US17/052,128 patent/US12227514B2/en active Active
- 2019-04-30 BR BR112020022186-4A patent/BR112020022186A2/pt not_active Application Discontinuation
- 2019-04-30 AU AU2019262286A patent/AU2019262286B2/en active Active
-
2023
- 2023-12-01 JP JP2023204100A patent/JP2024026251A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118451081A (zh) | Kras抑制剂的多晶型物及其制备方法和用途 | |
| CN103539795A (zh) | 阿哌沙班的多晶型及其制备方法 | |
| JP7111725B2 (ja) | １，３，５－トリアジン誘導体の塩およびその結晶、その製造方法、医薬組成物、ならびにそれらの使用 | |
| JP6457658B2 (ja) | 安定した、溶媒和物が含まれないアプレミラスト結晶形ｉｉ、及びその製造方法 | |
| ES2351958T3 (es) | 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-[2,3'] bipiridinil en forma cristalina pura y procedimiento de síntesis. | |
| JP6298768B2 (ja) | ７−置換ハンファンギチンｂ誘導体、その調製方法及び使用 | |
| JP2016528179A5 (enExample) | ||
| TW202444718A (zh) | 作為ｂ－ｒａｆ激酶二聚體抑制劑之化合物及其製備方法 | |
| CN110590749B (zh) | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 | |
| JP2022533340A5 (enExample) | ||
| JP2025131661A (ja) | ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 | |
| WO2023041026A1 (zh) | Rho相关蛋白激酶抑制剂或其溶剂合物的固体形式及其制备方法和用途 | |
| JP2025102940A5 (enExample) | ||
| JP2026041824A (ja) | テガビビントの結晶形態、調製方法、及びその使用 | |
| WO2013065063A1 (en) | Anhydrous form of dasatinib, process for its preparation and its use | |
| JP2018529769A (ja) | ニコチン酸イノシトールの結晶形ａおよびその製造方法 | |
| FI3789389T3 (fi) | (S)-N-[5-[l-(3-etoksi-4-metoksifenyyli)-2-(metyylisulfonyyli)etyyli]-4,6-diokso-5,6-dihydro-4H-tieno[3,4-c]pyrrol-1-yyli]asetamidin kidemuoto | |
| JP2015523349A (ja) | ポリフィリンｉのアシル化誘導体、その調製方法及び使用 | |
| CN105985349B (zh) | 七元环小檗碱类似物及其药物组合物、制备方法和用途 | |
| TW201829420A (zh) | [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式 | |
| KR102458566B1 (ko) | 메푸파리브 히드로클로라이드 다결정형 물질 및 이의 제조방법과 응용 | |
| JP6059734B2 (ja) | ２−アルキル−又は２−アリール−置換タンシノン誘導体、その調製方法及び適用 | |
| TW201827436A (zh) | 一種ｊａｋ激酶抑制劑的硫酸氫鹽的晶型及其製備方法 | |
| CN119431367A (zh) | 一种吡啶并吡唑衍生物的晶体形式及其制备方法和用途 | |
| JP7618575B2 (ja) | Ｎ－（５－（（４－エチルピペラジン－１－イル）メチル）ピリジン－２－イル）－５－フルオロ－４－（３－イソプロピル－２－メチル－２ｈ－インダゾール－５－イル）ピリミジン－２－アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用 |